Amer M Zeidan1, Franklin Hendrick2, Erika Friedmann3, Maria R Baer4, Steven D Gore1, Medha Sasane5, Carole Paley5, Amy J Davidoff6. 1. Department of Internal Medicine, Section of Hematology, Yale University, New Haven, CT 06520, USA. 2. Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA. 3. Department of Organizational Systems & Adult Health, University of Maryland School of Nursing, Baltimore, MD 21201, USA. 4. Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, MD 21201, USA. 5. Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA. 6. Department of Health Policy & Management, Yale School of Public Health, Yale University, New Haven, CT 06520, USA.
Abstract
AIMS: Iron overload adversely affects patients with myelodysplastic syndromes (MDS), but benefits of iron chelation therapy have not been clearly demonstrated. We examined the association between deferasirox (DFX) therapy and mortality in transfusion-receiving Medicare patients. PATIENTS & METHODS: MDS patients from 2005 to 2008 were identified using ICD-9 codes from 100% Medicare claims. Patients receiving ≥20 blood units were observed until death or end of study. Marginal structural models were used for estimation. RESULTS: 3926 patients (10.1% used DFX) were observed for a mean of 48.8 weeks. Each incremental week of DFX was associated with a significant reduction in mortality risk (hazard ratio [HR]: 0.989; 95% CI: 0.983-0.996; p = 0.001). CONCLUSION: DFX therapy is associated with a reduced mortality risk among older MDS patients who received a minimum transfusion threshold.
AIMS: Iron overload adversely affects patients with myelodysplastic syndromes (MDS), but benefits of iron chelation therapy have not been clearly demonstrated. We examined the association between deferasirox (DFX) therapy and mortality in transfusion-receiving Medicare patients. PATIENTS & METHODS:MDSpatients from 2005 to 2008 were identified using ICD-9 codes from 100% Medicare claims. Patients receiving ≥20 blood units were observed until death or end of study. Marginal structural models were used for estimation. RESULTS: 3926 patients (10.1% used DFX) were observed for a mean of 48.8 weeks. Each incremental week of DFX was associated with a significant reduction in mortality risk (hazard ratio [HR]: 0.989; 95% CI: 0.983-0.996; p = 0.001). CONCLUSION:DFX therapy is associated with a reduced mortality risk among older MDSpatients who received a minimum transfusion threshold.
Entities:
Keywords:
deferasirox; iron chelation therapy; iron overload; mortality; myelodysplastic syndromes
Authors: Heather A Leitch; Christopher Chan; Chantal S Leger; Lynda M Foltz; Khaled M Ramadan; Linda M Vickars Journal: Leuk Res Date: 2012-08-24 Impact factor: 3.156
Authors: Amy J Davidoff; Ilene H Zuckerman; Naimish Pandya; Franklin Hendrick; Xuehua Ke; Arti Hurria; Stuart M Lichtman; Arif Hussain; Jonathan P Weiner; Martin J Edelman Journal: J Geriatr Oncol Date: 2013-04 Impact factor: 3.599
Authors: Marlijn Hoeks; Ge Yu; Saskia Langemeijer; Simon Crouch; Louise de Swart; Pierre Fenaux; Argiris Symeonidis; Jaroslav Čermák; Eva Hellström-Lindberg; Guillermo Sanz; Reinhard Stauder; Mette Skov Holm; Moshe Mittelman; Krzysztof Mądry; Luca Malcovati; Aurelia Tatic; Antonio Medina Almeida; Ulrich Germing; Aleksandar Savic; Njetočka Gredelj Šimec; Dominic Culligan; Raphael Itzykson; Agnes Guerci-Bresler; Borhane Slama; Jackie Droste; Corine van Marrewijk; Arjan van de Loosdrecht; Nicole Blijlevens; Marian van Kraaij; David Bowen; Theo de Witte; Alex Smith Journal: Haematologica Date: 2019-07-05 Impact factor: 9.941